Our Products

Regensight holds in its capacity a CEI EN ISO 13485:2021 quality management system for design, manufacturing management and marketing of ophthalmic active medical devices and related sterile accessories. The notified body is TÜV Rheinland Italia.


UV-A medical device with exponential and key-enabling technologies


 0.22% riboflavin ophthalmic solution for corneal cross-linking

For professionals

To medical professionals

At the heart of our startup is the belief that revolutionary, life-changing, treatments of visual disorders needs courageous science and surgeon oriented perspective to deliver effective and safe outcomes to patients.In order to achieve the greatest benefit, our goal is to be representative of the eye surgeons’ needs to improve their patients’ care.

Do you want a product demonstration?
Contact us at customers@regensight.com

Do you have a project idea?
Contact us at 4social@regensight.com

For patient advocacy groups

Our startup strives to collaborate with patient advocacy groups understanding patients’ experiences, opinions and concerns in order to embed these perspectives into our decisions for the clinical development of products that truly know how to solve the unmet needs of patients.
Our goal is to design therapies and clinical trials that are representative of the communities we serve.
We deeply value the partnerships and collaborations.
Contact us at 4social@regensight.com


Regensight is establishing its global presence through selected authorized distibutors. marketing our high-technological medical products via out-licensing.
We are looking for partners in global markets providing high standards of service in the eye surgical sector to distribute our proprietary patented technology to serve world population.

If interested in our breakthrough product portfolio, please contact us at partnering@regensight.com, attaching a company curriculum and indicating your Territory of interest. Our Team will back to you soon.



Regensight is associated with Confindustria Medical Devices and Innovup.